This excerpt taken from the SGEN 10-K filed Mar 15, 2005.
SGN-70 and SGN-75
We are developing two preclinical product candidates that target the CD70 antigen: SGN-70 is a humanized monoclonal antibody with intrinsic cell-killing ability and SGN-75 is an ADC comprised of the same antibody linked to an Auristatin derivative using our second generation ADC technology. The CD70 antigen is expressed on renal cancer, nasopharyngeal carcinoma and certain hematologic malignancies. SGN-70 has demonstrated potent antitumor activity in preclinical models of hematologic malignancies. SGN-75 is highly effective and well tolerated in preclinical models of human renal cell cancer. Since CD70 is expressed on recently activated T- and B-cells, but not while those cells are in a resting, inactive state, SGN-70 and SGN-75 may also have applications in immunologic and inflammatory diseases. In preclinical studies, SGN-75 has been shown to selectively eliminate activated T-cells without affecting resting T-cells. SGN-70 and SGN-75 are both potential IND candidates in 2006 or 2007.